Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,010.00-5.41%ETH$2,233.05-7.48%GOLD$4,096.80-0.41%OIL$91.23+0.78%
Smart Investors Daily
SID Premium
SB

NASDAQ · SBFMW

Sunshine Biopharma, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$0.03

Up+$0.00 (+0.00%)

Updated Nov 6, 2026, 1:30 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
834.01K
P/E ratio
-0.05
Dividend yield
0.00%
52-week range
$0.02 – $0.65
Volume
5K
Avg. volume
11.77K

Price performance · SBFMW

SBFMW price history

1M range · 0 trading sessions · Daily adjusted prices

SBFMW does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SBFMW news

The latest Smart Investors Daily articles mentioning SBFMW.

Stock researchCompany · Overview

SBFMW research

Overview

Company profile and research snapshot.

Company profile

Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

FORT LAUDERDALE, FL / ACCESS Newswire / October 22, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced a one for twenty reverse split of its common stock, effective at market open on October 26, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.

Yahoo · Oct 9, 2026

Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrantsFORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company

Yahoo · Oct 8, 2026

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

FORT LAUDERDALE, FL / ACCESS Newswire / October 8, 2026 / (NASDAQ:SBFM) (the "Company"), a pharmaceutical company specializing in generic and specialty prescription medications, including drugs in the areas of oncology and antivirals, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By